Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1951 3
1952 1
1953 1
1954 1
1955 2
1956 1
1957 4
1958 1
1961 5
1962 6
1963 5
1964 6
1965 3
1966 11
1967 8
1968 13
1969 12
1970 19
1971 12
1972 16
1973 14
1974 17
1975 12
1976 6
1977 19
1978 17
1979 17
1980 27
1981 25
1982 35
1983 40
1984 48
1985 55
1986 47
1987 46
1988 45
1989 40
1990 52
1991 44
1992 57
1993 57
1994 47
1995 35
1996 61
1997 45
1998 55
1999 67
2000 75
2001 73
2002 49
2003 68
2004 53
2005 73
2006 57
2007 94
2008 125
2009 149
2010 127
2011 145
2012 136
2013 112
2014 102
2015 98
2016 111
2017 103
2018 114
2019 141
2020 158
2021 146
Text availability
Article attribute
Article type
Publication date

Search Results

3,237 results
Results by year
Filters applied: . Clear all
Page 1
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Among authors: kubota k. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. Among authors: kubota k. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8. N Engl J Med. 2017. PMID: 28885881 Free article. Clinical Trial.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. Among authors: kubota k. N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280658 Clinical Trial.
The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease.
Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF, Hart PA, Inoue D, Kawano M, Khosroshahi A, Kubota K, Lanzillotta M, Okazaki K, Perugino CA, Sharma A, Saeki T, Sekiguchi H, Schleinitz N, Stone JR, Takahashi N, Umehara H, Webster G, Zen Y, Stone JH; American College of Rheumatology/European League Against Rheumatism IgG4-Related Disease Classification Criteria Working Group. Wallace ZS, et al. Among authors: kubota k. Arthritis Rheumatol. 2020 Jan;72(1):7-19. doi: 10.1002/art.41120. Epub 2019 Dec 2. Arthritis Rheumatol. 2020. PMID: 31793250 Free article.
Clinical practice guidelines for IgG4-related sclerosing cholangitis.
Kamisawa T, Nakazawa T, Tazuma S, Zen Y, Tanaka A, Ohara H, Muraki T, Inui K, Inoue D, Nishino T, Naitoh I, Itoi T, Notohara K, Kanno A, Kubota K, Hirano K, Isayama H, Shimizu K, Tsuyuguchi T, Shimosegawa T, Kawa S, Chiba T, Okazaki K, Takikawa H, Kimura W, Unno M, Yoshida M. Kamisawa T, et al. Among authors: kubota k. J Hepatobiliary Pancreat Sci. 2019 Jan;26(1):9-42. doi: 10.1002/jhbp.596. Epub 2019 Jan 18. J Hepatobiliary Pancreat Sci. 2019. PMID: 30575336 Free PMC article.
Clinical guidelines for primary sclerosing cholangitis 2017.
Isayama H, Tazuma S, Kokudo N, Tanaka A, Tsuyuguchi T, Nakazawa T, Notohara K, Mizuno S, Akamatsu N, Serikawa M, Naitoh I, Hirooka Y, Wakai T, Itoi T, Ebata T, Okaniwa S, Kamisawa T, Kawashima H, Kanno A, Kubota K, Tabata M, Unno M, Takikawa H; PSC guideline committee Members: Ministry of Health, Labour and Welfare (Japan) Research Project, The Intractable Hepatobiliary Disease Study Group. Isayama H, et al. Among authors: kubota k. J Gastroenterol. 2018 Sep;53(9):1006-1034. doi: 10.1007/s00535-018-1484-9. Epub 2018 Jun 27. J Gastroenterol. 2018. PMID: 29951926
A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis.
Ikeda S, Kato T, Kenmotsu H, Ogura T, Iwasawa S, Sato Y, Harada T, Kubota K, Tokito T, Okamoto I, Furuya N, Yokoyama T, Hosokawa S, Iwasawa T, Yamanaka T, Okamoto H. Ikeda S, et al. Among authors: kubota k. J Thorac Oncol. 2020 Dec;15(12):1935-1942. doi: 10.1016/j.jtho.2020.08.018. Epub 2020 Aug 25. J Thorac Oncol. 2020. PMID: 32858235 Free PMC article. Clinical Trial.
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
Remon J, Passiglia F, Ahn MJ, Barlesi F, Forde PM, Garon EB, Gettinger S, Goldberg SB, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper KA, Skoulidis F, Reck M, Adjei AA, Scagliotti GV. Remon J, et al. Among authors: kubota k. J Thorac Oncol. 2020 Jun;15(6):914-947. doi: 10.1016/j.jtho.2020.03.006. Epub 2020 Mar 14. J Thorac Oncol. 2020. PMID: 32179179 Free article. Review.
3,237 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page